FAM174B and neoplasm: Experimental validation using the IMvigor210 cohort provided direct evidence linking high FAM174B expression with non-inflamed tumor characteristics, including diminished immune cell infiltration and reduced PD-L1 expression, ultimately resulting in poorer ICI response rates.